PINS Stimulator System for Deep Brain Stimulation to Treat Obesity
Early Phase 1
- Conditions
- Obesity
- Registration Number
- NCT02254395
- Lead Sponsor
- Beijing Pins Medical Co., Ltd
- Brief Summary
The purpose of this clinical study is to verify the long term effecacy and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd. as a treatment option for patients with obesity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Subject is aged 18 to 65.
- Body Mass Index [BMI] >40 kg/m2.
Exclusion Criteria
- Medical contraindications for general anesthesia, craniotomy, or DBS surgery
- Evidence of neurological disorders, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas.
- Participate in other clinical trial;
- Has a life expectancy of < 1 year.
- The investigator and/or enrollment review committee, would preclude participation in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Body Weight 12 month Body weight will be recorded at every follow-up visit.
- Secondary Outcome Measures
Name Time Method Body Mass Index (BMI) 12 month Food Intake 12 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of PINS Stimulator System in modulating hypothalamic pathways for obesity treatment?
How does bilateral deep brain stimulation from PINS compare to gastric bypass surgery in long-term weight management outcomes for morbid obesity?
Which neuroimaging biomarkers correlate with successful response to PINS DBS therapy in patients with BMI >40?
What are the potential adverse events associated with chronic hypothalamic stimulation using the PINS device and how are they managed?
Are there combination therapies involving PINS DBS and GLP-1 receptor agonists showing enhanced weight loss in treatment-resistant obesity?